STOCKS TELEGRAPH

Tag: Aptorum Group Stock

  • Investor Optimism Surges As Aptorum Group (APM) Confirms Merger

    Investor Optimism Surges As Aptorum Group (APM) Confirms Merger

    After the announcement of a definitive merger agreement with DiamiR Biosciences, Aptorum Group Limited (NASDAQ: APM) shares were surging 298.02% as of the latest check to trade at $3.86.

    DiamiR, which has a CLIA-licensed and CAP-accredited facility in New Haven, Connecticut, is well-known for creating unique blood-based diagnostic tools that target brain health and other complicated disorders.

    All-Stock Merger to Create Synergistic Life Sciences Firm

    After the merger, DiamiR Biosciences will become a fully-owned subsidiary of Aptorum Group through an all-stock transaction. APM will continue to trade on the Nasdaq Stock Market, while DiamiR will keep its name despite the merger.

    After considering a number of strategic alternatives, Aptorum’s board of directors concluded that this transaction has the best chance of producing both short-term and long-term shareholder value.

    Aligning Strategically for International Growth

    According to Aptorum’s leadership, the integration of DiamiR’s expertise will position the combined entity to emerge as a globally focused life sciences company. The merged organization aims to generate revenue from biopharma services and deliver innovative biomarker panels designed to better characterize patients with complex biology, including those affected by neurodegenerative and autoimmune disorders.

    The partnership is expected to accelerate DiamiR’s clinical and pharmaceutical service offerings, with a strong emphasis on aging-related diseases such as Alzheimer’s.

    Merger Structure and Future Operations

    Prior to the merger’s closing, Aptorum will re-domicile to the state of Delaware. Post-domestication, APM will acquire all outstanding shares of DiamiR in exchange for newly issued common stock, resulting in DiamiR shareholders owning approximately 70% of the combined company.

    Existing Aptorum shareholders will retain the remaining 30%. The merged entity will establish its headquarters in Princeton, New Jersey. Five directors will make up its board: three will be chosen by APM, and two will be chosen by DiamiR, along with one board observer.

    Aptorum’s path to becoming a major force in non-invasive diagnostics and cutting-edge life sciences solutions has undergone a sea change with this strategic consolidation.

  • Aptorum (APM) Sees An Astounding Spike, Propelled By A Significant Merger Plan

    Aptorum (APM) Sees An Astounding Spike, Propelled By A Significant Merger Plan

    Aptorum Group Limited (NASDAQ: APM) is witnessing a remarkable surge of 595.49%, reaching $11.61 in current session today, a spike attributed to an impending merger. Aptorum (APM), unveiled an Agreement and Plan of Merger with privately-held YOOV Group Holding Ltd., a move endorsed by both entities’ boards of directors.

    Pending shareholder approval from Aptorum and YOOV, along with the execution of the merger’s transactions, a subsidiary of Aptorum will integrate with YOOV, marked as a significant step forward. Furthermore, on March 1, 2024, Aptorum, its principal shareholder Jurchen Investment Corporation (controlled by Ian Huen, Executive Director and CEO of Aptorum), and its subsidiary Aptorum Therapeutics Limited (ATL) have entered into a split-off agreement.

    This agreement entails the transfer of Aptorum’s legacy business assets and liabilities to ATL, with Jurchen acquiring all issued shares of ATL from Aptorum and relinquishing certain ordinary shares back to Aptorum. The separation, effective post-merger completion, alongside the merger, constitutes the “Proposed Transactions,” with the resultant entity termed the “combined company.”

    Post-merger, existing shareholders of Aptorum and YOOV are poised to hold roughly 10% and 90% of the combined company’s outstanding shares, respectively. Aptorum has agreed to issue Class A and Class B ordinary shares to YOOV’s shareholders, with the number of shares determined by the “Conversion Ratio.”

    This ratio, calculated based on Aptorum’s existing shares multiplied by nine, divided by YOOV’s fully diluted shares, will ascertain the issuance. Characterized as a “reverse merger,” this arrangement grants YOOV shareholders majority ownership of the combined entity, necessitating NASDAQ’s approval for the new entity’s initial listing.

    The merger signifies a strategic move for Aptorum, positioning it for substantial growth and market expansion under the combined entity’s umbrella. Aptorum Group Limited’s surge in stock value on US stock charts reflects investor optimism surrounding its merger with YOOV Group Holding Ltd.

    This strategic move, coupled with a subsequent split-off agreement, is poised to reshape Aptorum’s business landscape, subject to regulatory approval, heralding a new era of growth and opportunity for the company.